228 related articles for article (PubMed ID: 22285607)
1. Molecular resistance: an early indicator for treatment change?
Fava C; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):79-87. PubMed ID: 22285607
[TBL] [Abstract][Full Text] [Related]
2. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
[TBL] [Abstract][Full Text] [Related]
4. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
[TBL] [Abstract][Full Text] [Related]
5. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.
Parker WT; Lawrence RM; Ho M; Irwin DL; Scott HS; Hughes TP; Branford S
J Clin Oncol; 2011 Nov; 29(32):4250-9. PubMed ID: 21990409
[TBL] [Abstract][Full Text] [Related]
6. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
O'Hare T; Eide CA; Deininger MW
Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
[TBL] [Abstract][Full Text] [Related]
7. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
8. Loss of response to imatinib: mechanisms and management.
Shah NP
Hematology Am Soc Hematol Educ Program; 2005; ():183-7. PubMed ID: 16304378
[TBL] [Abstract][Full Text] [Related]
9. Therapy options in imatinib failures.
Ramirez P; DiPersio JF
Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
[TBL] [Abstract][Full Text] [Related]
10. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.
Stein B; Smith BD
Clin Ther; 2010 May; 32(5):804-20. PubMed ID: 20685492
[TBL] [Abstract][Full Text] [Related]
11. Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment.
Bauer RC; Sänger J; Peschel C; Duyster J; von Bubnoff N
Clin Cancer Res; 2013 Jun; 19(11):2962-72. PubMed ID: 23549879
[TBL] [Abstract][Full Text] [Related]
12. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
von Bubnoff N; Manley PW; Mestan J; Sanger J; Peschel C; Duyster J
Blood; 2006 Aug; 108(4):1328-33. PubMed ID: 16614241
[TBL] [Abstract][Full Text] [Related]
13. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Jabbour E; Branford S; Saglio G; Jones D; Cortes JE; Kantarjian HM
Cancer; 2011 May; 117(9):1800-11. PubMed ID: 21509757
[TBL] [Abstract][Full Text] [Related]
14. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
[TBL] [Abstract][Full Text] [Related]
15. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
[TBL] [Abstract][Full Text] [Related]
16. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
Soverini S; Rosti G; Iacobucci I; Baccarani M; Martinelli G
Oncologist; 2011; 16(6):868-76. PubMed ID: 21632458
[TBL] [Abstract][Full Text] [Related]
17. Overcoming kinase resistance in chronic myeloid leukemia.
Lee F; Fandi A; Voi M
Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.
Barańska M; Lewandowski K; Gniot M; Iwoła M; Lewandowska M; Komarnicki M
J Appl Genet; 2008; 49(2):201-3. PubMed ID: 18436994
[TBL] [Abstract][Full Text] [Related]
19. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
Kantarjian H; Cortes J
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S37-42; quiz S43-S44. PubMed ID: 18397680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
